Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec 13;20(24):6305.
doi: 10.3390/ijms20246305.

The Challenge of Bringing iPSCs to the Patient

María Del Carmen Ortuño-Costela  1   2 , Victoria Cerrada  2 , Marta García-López  2 , M Esther Gallardo  2   3
Affiliations
Review

The Challenge of Bringing iPSCs to the Patient

María Del Carmen Ortuño-Costela et al. Int J Mol Sci. .

Abstract

The implementation of induced pluripotent stem cells (iPSCs) in biomedical research more than a decade ago, resulted in a huge leap forward in the highly promising area of personalized medicine. Nowadays, we are even closer to the patient than ever. To date, there are multiple examples of iPSCs applications in clinical trials and drug screening. However, there are still many obstacles to overcome. In this review, we will focus our attention on the advantages of implementing induced pluripotent stem cells technology into the clinics but also commenting on all the current drawbacks that could hinder this promising path towards the patient.

Keywords: clinical trial; clinics; drug screening; iPSCs; induced pluripotent stem cells; personalized medicine; regenerative medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Timeline of the most important milestones from the discovery of induced pluripotent stem cells (iPSCs) in 2006 to now in 2019.
Figure 2
Figure 2
Principal hurdles encountered when translating iPSCs to the clinics.
See this image and copyright information in PMC

References

    1. Takahashi K., Yamanaka S., Zhang Y., Li Y., Feng C., Li X., Lin L., Guo L., Wang H., Liu C., et al. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–676. doi: 10.1016/j.cell.2006.07.024. - DOI - PubMed
    1. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–872. doi: 10.1016/j.cell.2007.11.019. - DOI - PubMed
    1. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917–1920. doi: 10.1126/science.1151526. - DOI - PubMed
    1. Choi J., Lee S., Clement K., Mallard W., Tagliazucchi G.M., Lim H., Choi I.Y., Ferrari F., Tsankov A., Pop R., et al. A comparison of genetically matched cell lines reveals the equivalence of human iPSCs and ESCs. Nat. Biotechnol. 2016;25:289–313. doi: 10.1038/nbt.3388. - DOI - PMC - PubMed
    1. Shi Y., Inoue H., Wu J.C., Yamanaka S. Induced pluripotent stem cell technology: A decade of progress. Nat. Rev. Drug Discov. 2017;16:115–130. doi: 10.1038/nrd.2016.245. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources